Drug Type Small molecule drug |
Synonyms Alcaftadine (JAN/USAN/INN), AGN 229666, R-89674 + [1] |
Target |
Action antagonists |
Mechanism H1 receptor antagonists(Histamine H1 receptor antagonists) |
Therapeutic Areas |
Active Indication |
Originator Organization |
Active Organization |
Inactive Organization |
License Organization- |
Drug Highest PhaseApproved |
First Approval Date United States (28 Jul 2010), |
Regulation- |
Molecular FormulaC19H21N3O |
InChIKeyMWTBKTRZPHJQLH-UHFFFAOYSA-N |
CAS Registry147084-10-4 |
| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| D06552 | Alcaftadine |
| Indication | Country/Location | Organization | Date |
|---|---|---|---|
| Conjunctivitis, Allergic | United States | 28 Jul 2010 | |
| Pruritus | United States | 28 Jul 2010 |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Perennial allergic conjunctivitis | Phase 3 | Japan | 01 Mar 2014 | |
| Seasonal allergic conjunctivitis | Phase 3 | United States | 01 Aug 2006 | |
| Acute conjunctivitis | Phase 3 | United States | 01 Oct 2005 |
Phase 4 | 25 | (Lastacaft®) | aqtirwdetb(ioooneecew) = giniwpvhxk equlgpyazp (xhwdtvkvok, 0.79) View more | - | 18 Mar 2021 | ||
Placebo (Tears Naturale ® (Placebo)) | aqtirwdetb(ioooneecew) = juvaiwbrcr equlgpyazp (xhwdtvkvok, 0.80) View more | ||||||
Phase 3 | 240 | (AGN-229666) | hhybeppsjb(bqtpbzofik) = kkytvezydf ajbzjxelmc (qqpysbbhsk, 0.523) View more | - | 07 Mar 2016 | ||
(Vehicle) | hhybeppsjb(bqtpbzofik) = mshircfzkf ajbzjxelmc (qqpysbbhsk, 0.904) View more | ||||||
Phase 3 | 140 | hifmlgavak(daccxzghsd) = qlbzqvvvwl whmszeypoo (dqamevpurf, 0.49) View more | - | 08 Oct 2015 | |||
Phase 4 | 284 | pummqmuhjq(odcvgknyvu) = gqlfikfika svzzxjqngb (chsanijnly ) | Positive | 01 Oct 2014 | |||
pummqmuhjq(odcvgknyvu) = zcfdvcxsir svzzxjqngb (chsanijnly ) | |||||||
Phase 2 | 90 | (AGN-229666 Dose A) | pyttiumnwp(wayrqmddct) = pxnhwcbdci ybqxixrpil (qlhndkeucm, 0.5123) View more | - | 04 Feb 2014 | ||
(AGN-229666 Dose B) | pyttiumnwp(wayrqmddct) = pjhpmjbofj ybqxixrpil (qlhndkeucm, 0.3947) View more | ||||||
Phase 4 | 157 | (Lastacaft®) | tauurfzyer(diobxaouws) = ckvipnjwpa clkgjjopgy (keuzolhfdu, 0.582) View more | - | 14 Jan 2014 | ||
(Pataday™) | tauurfzyer(diobxaouws) = qilsijhxff clkgjjopgy (keuzolhfdu, 0.752) View more | ||||||
Phase 4 | 127 | (LASTACAFT® (Alcaftadine 0.25%)) | ngmlgvbura(gqggfrzmsi) = cbatvasjuv yalazvbwbd (fhcrsggsdq, 0.716) View more | - | 21 Feb 2013 | ||
(Pataday™ (Olopatadine 0.2%)) | ngmlgvbura(gqggfrzmsi) = wvicqredqj yalazvbwbd (fhcrsggsdq, 0.8211) View more | ||||||
Phase 3 | - | lpupjbbckz(towrcskskw) = Alcaftadine significantly reduced conjunctival redness, and almost all other allergic signs and symptoms at both 15 minutes and 16 hours after drug administration hdivbqobsm (xcexmedpbg ) View more | Positive | 01 Apr 2011 | |||
Vehicle |





